New Delhi: Drug firm Zydus Cadila Saturday said it has received approval from the US health regulator to market Albendazole Tablets, used in treating certain tapeworm infections, in the American market.
The company has received the final approval from the US Food and Drug Administration (USFDA) to market Albendazole Tablets USP in the strength of 200 mg, Zydus Cadila said in a statement.
The company’s product will be manufactured at Zydus group’s formulations manufacturing facility at Ahmedabad.
It also received tentative approval from the USFDA for Pregabalin capsules, used to help control certain kinds of seizures, in multiple strengths ranging from 25 mg to 300 mg.
The product will be manufactured at its plant at Moraiya, Ahmedabad.
Zydus group now has 239 approvals from the USFDA and has so far filed over 340 abbreviated new drug applications (ANDAs) since the commencement of its filing process in 2003-04.
Latest posts by MD Team (see all)
- Recordati to seek Canadian approval for kidney disease drug Cystagon - April 17, 2019
- Wockhardt gets zero USFDA observations for Bioequivalence centre - April 16, 2019
- Amgen sets over Rs 15 lakh yearly price for new bone drug Evenity - April 16, 2019